---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-017157"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T00:47:56.847447+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics Q1 revenue $59M via Janssen termination; cuts workforce, runway to 2H25

## Summary
- Q1 GAAP operating expenses $87.6M including $12.9M severance; revenue includes $52.3M from Janssen termination.
- Cash, cash equivalents & investments $412.8M; with $13.5M receivables, expects >$300M at year-end 2023.
- Discontinued Janssen collaboration, withdrew IND; terminated NK programs FT516, FT596, FT538, FT536.
- Workforce reduced to ~220 employees; 2023 GAAP op-ex guidance $265M-$285M.
- FT576 enrolling multi-dose cohorts; FT522 IND submitted; FT819 advancing; HER2 IND planned 2H23.

## SEC filing metadata
- accession: 0000950170-23-017157
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017023017157/0000950170-23-017157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017023017157/fate-20230503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-017157
- JSON: https://secwatch.observer/filing/0000950170-23-017157.json
- Plain text: https://secwatch.observer/filing/0000950170-23-017157.txt

## Key facts
- Earnings Releases
  FATE THERAPEUTICS INC reported financial results for first quarter ended March 31, 2023.
  - Period: first quarter ended March 31, 2023
  - Result: reported results
  source text: On May 3, 2023, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000095017023017157/0000950170-23-017157-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.